Boehringer Ingelheim: Hypertension trials

The registry lists 122 Hypertension studies with Boehringer Ingelheim as lead sponsor. 1 are open to participants now and 41 have results posted.

Phase 1 1Phase 2 4Phase 3 43Phase 4 26No phase 48(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPMCompletedNCT00274612Phase 4
• PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTNCompletedNCT00274599Phase 4
• Inflammation and Coronary Artery Disease: Role of AT1-Receptor AntagonismCompletedNCT00274144Phase 4
• DETAIL Study: Diabetes Exposed to Telmisartan and EnalaprilCompletedNCT00274118Phase 3
• SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk PatientsTerminatedNCT00274105Phase 4
• Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive PatientsCompletedNCT00267943Phase 3
• Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential HypertensionCompletedNCT00257491Phase 3
• Blood Pressure Reduction in Danish General Practice (BRIDGE)CompletedNCT00244660Phase 4
• Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma ActivitiesCompletedNCT00242814Phase 4
• A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)CompletedNCT00240474Phase 4
• A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II PatientsCompletedNCT00240448Phase 4
• Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 DiabetesCompletedNCT00240422Phase 4
• SMOOTH - Blood Pressure Control in Diabetic/Obese PatientsCompletedNCT00239538Phase 4
• Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5CompletedNCT00239369Phase 3
• A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)CompletedNCT00168857Phase 4
• Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 HypertensionCompletedNCT00168779Phase 4
• 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential HypertensionCompletedNCT00153049Phase 2
• 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt NephropathyCompletedNCT00153023Phase 4
• Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mgCompletedNCT00146341Phase 3
• Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan MonotherapyCompletedNCT00144222Phase 3
• A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate HypertensionCompletedNCT00133185Phase 3
• Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed DoseCompletedNCT00034840Phase 4